Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model

Br J Haematol. 2017 Nov;179(3):508-510. doi: 10.1111/bjh.14229. Epub 2016 Jul 22.

Authors

Affiliations

¹ Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.
² Leukemia/Bone Marrow Transplant Program of British Columbia, British Columbia Cancer Agency, Vancouver, BC, Canada.
³ Centre for Lymphoid Cancer and Department of Pathology, British Columbia Cancer Agency, Vancouver, BC, Canada.

PMID: 27443424
DOI: 10.1111/bjh.14229

No abstract available

Keywords: CNS relapse; diffuse large B-cell lymphoma; rituximab.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols
Biopsy
Central Nervous System Neoplasms / diagnosis*
Central Nervous System Neoplasms / drug therapy
Central Nervous System Neoplasms / mortality
Central Nervous System Neoplasms / secondary*
Cyclophosphamide
Doxorubicin
Humans
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / pathology*
Models, Statistical*
Prednisone
Prognosis
Risk Assessment
Rituximab
Treatment Outcome
Vincristine

Substances

Antibodies, Monoclonal, Murine-Derived
R-CHOP protocol
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone